{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:55:48Z","timestamp":1782863748619,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100025019","name":"Support for Pioneering Research Initiated by the Next Generation","doi-asserted-by":"crossref","award":["JPMJSP2135"],"award-info":[{"award-number":["JPMJSP2135"]}],"id":[{"id":"10.13039\/501100025019","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06275"],"award-info":[{"award-number":["23K06275"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018502","name":"Kanazawa University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018502","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Currently, no established treatments for disseminated intravascular coagulation (DIC) specifically target fibrinolysis. We previously demonstrated that prophylactic administration of tissue plasminogen activator (tPA) to a lipopolysaccharide (LPS)-induced rat DIC model improved DIC pathophysiology. However, the optimal duration of tPA administration and its effectiveness when administered therapeutically remain unclear. In the present study, we investigated whether tPA remains effective when administered at the same dosage over different durations, and whether therapeutic administration is also effective. We found that both prophylactic and therapeutic administration of tPA increased D-dimer levels, reduced serum creatinine and the renal glomerular fibrin deposition rate, suppressed the formation of thrombin\u2013antithrombin complex and interleukin-6, and attenuated decreases in platelet count. Furthermore, with both prophylactic and therapeutic administration of tPA, most markers of DIC pathophysiology demonstrated greater improvements with longer administration of tPA, from 15\u00a0min to 8\u00a0h. No bleeding tendency was observed based on urinary hemoglobin levels. These results suggest that a lower tPA dose rate and longer duration of administration may enhance efficacy and safety in the LPS-induced rat DIC model. A reduced dosage and extended duration of tPA administration could represent a new treatment option for clinical DIC and warrants further investigation.<\/jats:p>","DOI":"10.1007\/s12185-026-04187-1","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:41:42Z","timestamp":1773049302000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolonged low-dose tPA ameliorates coagulopathy and organ injury in an LPS-induced rat DIC model"],"prefix":"10.1007","volume":"124","author":[{"given":"Rina","family":"Takenaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoka","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-2994","authenticated-orcid":false,"given":"Yukio","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidesaku","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"4187_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1055\/s-0037-1615899","volume":"82","author":"M Levi","year":"1999","unstructured":"Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost. 1999;82:695\u2013705.","journal-title":"Thromb Haemost"},{"key":"4187_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1055\/s-0042-1756300","volume":"48","author":"T Iba","year":"2022","unstructured":"Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost. 2022;48:978\u201387.","journal-title":"Semin Thromb Hemost"},{"key":"4187_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2052-0492-2-20","volume":"2","author":"H Asakura","year":"2014","unstructured":"Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.","journal-title":"J Intensive Care"},{"key":"4187_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-020-03030-5","volume":"113","author":"H Asakura","year":"2021","unstructured":"Asakura H. Diversity of disseminated intravascular coagulation and selection of appropriate treatments. Int J Hematol. 2021;113:10\u20134.","journal-title":"Int J Hematol"},{"key":"4187_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/01.mbc.0000061290.28953.57","volume":"14","author":"H Asakura","year":"2003","unstructured":"Asakura H, Suga Y, Yoshida T, Ontachi Y, Mizutani T, Kato M, et al. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats. Blood Coagul Fibrinolysis. 2003;14:221\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"4187_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12185-021-03158-y","volume":"114","author":"Y Suga","year":"2021","unstructured":"Suga Y, Kubo A, Katsura H, Staub Y, Tashiro K, Yamada S, et al. Detailed exploration of pathophysiology involving inflammatory status and bleeding symptoms between lipopolysaccharide- and tissue factor-induced disseminated intravascular coagulation in rats. Int J Hematol. 2021;114:172\u20138.","journal-title":"Int J Hematol"},{"key":"4187_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jphs.2017.01.005","volume":"133","author":"H Minomo","year":"2017","unstructured":"Minomo H, Inoue K, Sakaki S, Okazaki T, Kobayashi K, Miyata A. Establishment of disseminated intravascular coagulation (DIC) model by a single iv administration of Escherichia coli-derived lipopolysaccharide (LPS) to cynomolgus monkeys and evaluation of its pathophysiological status. J Pharmacol Sci. 2017;133:88\u201395.","journal-title":"J Pharmacol Sci"},{"key":"4187_CR8","doi-asserted-by":"publisher","DOI":"10.1590\/acb351102","volume":"35","author":"A \u00d6ahin","year":"2020","unstructured":"\u00d6ahin A, \u00d6zer N. The effect of activated protein C in the experimental disseminated intravascular coagulation model formed by lipopolysaccharide infusion. Acta Cir Bras. 2020;35:e351102.","journal-title":"Acta Cir Bras"},{"key":"4187_CR9","first-page":"757","volume":"89","author":"H Asakura","year":"2004","unstructured":"Asakura H, Sano Y, Yamazaki M, Morishita E, Miyamoto K, Nakao S. Role of fibrinolysis in tissue-factor-induced disseminated intravascular coagulation in rats - an effect of tranexamic acid. Haematologica. 2004;89:757\u20138.","journal-title":"Haematologica"},{"key":"4187_CR10","first-page":"593","volume":"15","author":"Y Suga","year":"2004","unstructured":"Suga Y, Asakura H, Yoshida T, Omote M, Ontachi Y, Mizutani T, et al. Relationship between endothelin and the pathophysiology of tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation in rats: a study examining the effect of an endothelin receptor antagonist. Blood Coagul Fibrinolysis. 2004;15:593\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"4187_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111869","author":"S Murao","year":"2019","unstructured":"Murao S, Yamakawa K. A systematic summary of systematic reviews on anticoagulant therapy in sepsis. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8111869.","journal-title":"J Clin Med"},{"key":"4187_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31\u201341.","journal-title":"J Thromb Haemost"},{"key":"4187_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.thromres.2021.08.014","volume":"206","author":"Y Suga","year":"2021","unstructured":"Suga Y, Tashiro K, Staub Y, Komura S, Yamada S, Morishita E, et al. Potential of continuous tPA infusion for multiple-organ failure from lipopolysaccharide-induced disseminated intravascular coagulation in rats. Thromb Res. 2021;206:84\u20137.","journal-title":"Thromb Res"},{"key":"4187_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","year":"1995","unstructured":"The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581\u20137.","journal-title":"N Engl J Med"},{"key":"4187_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/1060028015579988","volume":"49","author":"K Brandt","year":"2015","unstructured":"Brandt K, McGinn K, Quedado J. Low-dose systemic Alteplase (tPA) for the treatment of pulmonary embolism. Ann Pharmacother. 2015;49:818\u201324.","journal-title":"Ann Pharmacother"},{"key":"4187_CR16","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1097\/01.CCM.0000133667.86429.5D","volume":"32","author":"W Zenz","year":"2004","unstructured":"Zenz W, Zoehrer B, Levin M, Fanconi S, Hatzis TD, Knight G, et al. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med. 2004;32:1777\u201380.","journal-title":"Crit Care Med"},{"key":"4187_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47630-6","volume":"9","author":"C Schoergenhofer","year":"2019","unstructured":"Schoergenhofer C, Buchtele N, Gelbenegger G, Derhaschnig U, Firbas C, Kovacevic KD, et al. Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers. Sci Rep. 2019;9:11136.","journal-title":"Sci Rep"},{"key":"4187_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/bloodadvances.2020003046","volume":"5","author":"EP Mihalko","year":"2021","unstructured":"Mihalko EP, Sandry M, Mininni N, Nellenbach K, Deal H, Daniele M, et al. Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation. Blood Adv. 2021;5:613\u201327.","journal-title":"Blood Adv"},{"key":"4187_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/STROKEAHA.119.027921","volume":"51","author":"M Marko","year":"2020","unstructured":"Marko M, Posekany A, Szabo S, Scharer S, Kiechl S, Knoflach M, et al. Trends of r-tPA (recombinant tissue-type plasminogen activator) treatment and treatment-influencing factors in acute ischemic stroke. Stroke. 2020;51:1240\u20137.","journal-title":"Stroke"},{"key":"4187_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"W Hacke","year":"2008","unstructured":"Hacke W, Kaste M, Bluhmki E, Brozman M, D\u00e1valos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317\u201329.","journal-title":"N Engl J Med"},{"key":"4187_CR21","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1182\/blood.V72.5.1467.1467","volume":"72","author":"VW van Hinsbergh","year":"1988","unstructured":"van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988;72:1467\u201373.","journal-title":"Blood"},{"key":"4187_CR22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1084\/jem.163.5.1260","volume":"163","author":"JJ Emeis","year":"1986","unstructured":"Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med. 1986;163:1260\u20136.","journal-title":"J Exp Med"},{"key":"4187_CR23","doi-asserted-by":"publisher","first-page":"19095","DOI":"10.1016\/S0021-9258(17)32279-2","volume":"269","author":"AM Healy","year":"1994","unstructured":"Healy AM, Gelehrter TD. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1994;269:19095\u2013100.","journal-title":"J Biol Chem"},{"key":"4187_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1083\/jcb.113.6.1413","volume":"113","author":"RR Schleef","year":"1991","unstructured":"Schleef RR, Loskutoff DJ, Podor TJ. Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells. J Cell Biol. 1991;113:1413\u201323.","journal-title":"J Cell Biol"},{"key":"4187_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ajh.20089","volume":"76","author":"K Okabayashi","year":"2004","unstructured":"Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis\u2010related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol. 2004;76:225\u20139.","journal-title":"Am J Hematol"},{"key":"4187_CR26","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1097\/01.CCM.0000128445.95144.B8","volume":"32","author":"R Pawlinski","year":"2004","unstructured":"Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med. 2004;32:S293\u20137.","journal-title":"Crit Care Med"},{"key":"4187_CR27","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1182\/blood-2003-09-3051","volume":"103","author":"R Pawlinski","year":"2004","unstructured":"Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004;103:1342\u20137.","journal-title":"Blood"},{"key":"4187_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2174\/157016112801784549","volume":"10","author":"T van der Poll","year":"2012","unstructured":"van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol. 2012;10:632\u20138.","journal-title":"Curr Vasc Pharmacol"},{"key":"4187_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MBC.0b013e328346ef3f","volume":"22","author":"EM Egorina","year":"2011","unstructured":"Egorina EM, Sovershaev MA, Hansen JB. The role of tissue factor in systemic inflammatory response syndrome. Blood Coagul Fibrinolysis. 2011;22:451\u20136.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"4187_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/aji.12517","volume":"76","author":"MV Mhatre","year":"2016","unstructured":"Mhatre MV, Potter JA, Lockwood CJ, Krikun G, Abrahams VM. Thrombin augments LPS-induced human endometrial endothelial cell inflammation via PAR1 activation. Am J Reprod Immunol. 2016;76:29\u201337.","journal-title":"Am J Reprod Immunol"},{"key":"4187_CR31","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1055\/s-0038-1655767","volume":"118","author":"C Schoergenhofer","year":"2018","unstructured":"Schoergenhofer C, Schwameis M, Gelbenegger G, Buchtele N, Thaler B, Mussbacher M, et al. Inhibition of protease-activated receptor (PAR1) reduces activation of the endothelium, coagulation, fibrinolysis and inflammation during human endotoxemia. Thromb Haemost. 2018;118:1176\u201384.","journal-title":"Thromb Haemost"},{"key":"4187_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/01.WCB.0000055177.50448.FA","volume":"23","author":"O Herrmann","year":"2003","unstructured":"Herrmann O, Tarabin V, Suzuki S, Attigah N, Coserea I, Schneider A, et al. Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. J Cereb Blood Flow Metab. 2003;23:406\u201315.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4187_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/STROKEAHA.122.040529","volume":"54","author":"JJ McCabe","year":"2023","unstructured":"McCabe JJ, Walsh C, Gorey S, Harris K, Hervella H, Iglesias-Rey R, et al. C-reactive protein, interleukin-6, and vascular recurrence after stroke: an individual participant data meta-analysis. Stroke. 2023;54:1289\u201399.","journal-title":"Stroke"},{"key":"4187_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1538574413497107","volume":"47","author":"N Skeik","year":"2013","unstructured":"Skeik N, Gits CC, Ehrenwald E, Cragg AH. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis. Vasc Endovascular Surg. 2013;47:519\u201323.","journal-title":"Vasc Endovascular Surg"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04187-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:09:04Z","timestamp":1782860944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04187-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4187"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04187-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}